AU2017367699B2 - Fracture targeted bone regeneration through parathyroid hormone receptor stimulation - Google Patents

Fracture targeted bone regeneration through parathyroid hormone receptor stimulation Download PDF

Info

Publication number
AU2017367699B2
AU2017367699B2 AU2017367699A AU2017367699A AU2017367699B2 AU 2017367699 B2 AU2017367699 B2 AU 2017367699B2 AU 2017367699 A AU2017367699 A AU 2017367699A AU 2017367699 A AU2017367699 A AU 2017367699A AU 2017367699 B2 AU2017367699 B2 AU 2017367699B2
Authority
AU
Australia
Prior art keywords
glu glu
ser
asp asp
lys
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017367699A
Other languages
English (en)
Other versions
AU2017367699A1 (en
AU2017367699A8 (en
Inventor
Philip S. Low
Stewart Andrew LOW
Jeffery Jay Howard NIELSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of AU2017367699A1 publication Critical patent/AU2017367699A1/en
Publication of AU2017367699A8 publication Critical patent/AU2017367699A8/en
Application granted granted Critical
Publication of AU2017367699B2 publication Critical patent/AU2017367699B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017367699A 2016-11-30 2017-11-30 Fracture targeted bone regeneration through parathyroid hormone receptor stimulation Active AU2017367699B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662428492P 2016-11-30 2016-11-30
US62/428,492 2016-11-30
US201762553313P 2017-09-01 2017-09-01
US62/553,313 2017-09-01
PCT/US2017/064081 WO2018102616A1 (en) 2016-11-30 2017-11-30 Fracture targeted bone regeneration through parathyroid hormone receptor stimulation

Publications (3)

Publication Number Publication Date
AU2017367699A1 AU2017367699A1 (en) 2019-07-11
AU2017367699A8 AU2017367699A8 (en) 2019-07-25
AU2017367699B2 true AU2017367699B2 (en) 2023-12-07

Family

ID=62241919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017367699A Active AU2017367699B2 (en) 2016-11-30 2017-11-30 Fracture targeted bone regeneration through parathyroid hormone receptor stimulation

Country Status (10)

Country Link
US (3) US20200317745A1 (enExample)
EP (1) EP3548012A4 (enExample)
JP (2) JP7649624B2 (enExample)
CN (1) CN110114065A (enExample)
AU (1) AU2017367699B2 (enExample)
BR (1) BR112019011070A2 (enExample)
CA (1) CA3045458A1 (enExample)
IL (1) IL266977B2 (enExample)
MX (1) MX2019006189A (enExample)
WO (1) WO2018102616A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
EP3796941A4 (en) * 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
CN110551201B (zh) * 2019-08-26 2020-04-28 杭州彗搏科技有限公司 一种新型骨形成蛋白2来源的环肽、制备方法及其应用
CN114364327A (zh) * 2019-09-12 2022-04-15 雷迪厄斯健康公司 用阿巴帕肽改善脊柱融合的方法
CN112646042A (zh) * 2019-10-10 2021-04-13 陕西麦科奥特科技有限公司 活性多肽化合物
WO2022051555A2 (en) * 2020-09-03 2022-03-10 Rampart Bioscience, Inc. Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures
JP2023547889A (ja) * 2020-10-26 2023-11-14 パーデュー・リサーチ・ファウンデーション 脊椎融合を治療するための化合物、組成物、および使用の方法
AU2022205801A1 (en) * 2021-01-05 2023-07-13 Radius Health, Inc. Treatment of long bone fractures with abaloparatide
WO2023136866A1 (en) * 2022-01-14 2023-07-20 Novosteo Llc Bone targeted treatment in osteogenesis imperfecta
WO2024246840A1 (en) * 2023-06-01 2024-12-05 Radius Health, Inc. Methods for identification and quantitation of abaloparatide and related peptide impurities
WO2025019691A1 (en) * 2023-07-19 2025-01-23 Zymeron Corporation Drug conjugates for bone marrow protection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060199765A1 (en) * 1998-12-31 2006-09-07 Gardella Thomas J PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
JP2010523671A (ja) * 2007-04-09 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合領域と副甲状腺ホルモンとの融合タンパク
JP2010526543A (ja) * 2007-05-11 2010-08-05 エノビア ファルマ インコーポレイテッド 骨標的アルカリホスファターゼ、キット及びその使用方法
US20150246957A1 (en) * 2012-08-28 2015-09-03 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9103791A (en) * 1990-12-21 1992-07-22 Allelix Biopharmaceuticals Inc. Oxidation resistant variants of parathyroid hormone
WO1995002610A1 (en) * 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
EP1950224A3 (en) * 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
JP2000327583A (ja) 1999-05-17 2000-11-28 Medei Sci Puraningu:Kk 骨指向性ホルモン誘導体
WO2004062588A2 (en) * 2003-01-06 2004-07-29 University Of Utah Water-soluble polymeric bone-targeting drug delivery system
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
JP5375611B2 (ja) 2006-10-03 2013-12-25 ラジウス ヘルス，インコーポレイテッド 骨同化作用を有するタンパク質のための薬物送達方法
WO2009141823A2 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
US20130006217A1 (en) * 2011-04-22 2013-01-03 Gary Hattersley METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
CN102824647B (zh) * 2011-06-13 2014-07-23 香港中文大学 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法
EP3016674A4 (en) 2013-06-23 2017-03-15 Wisconsin Alumni Research Foundation Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same
EP4137147A3 (en) * 2015-03-03 2023-04-05 Radius Health, Inc. Uses of abaloparatide in reducing fracture risk
WO2016196400A1 (en) * 2015-05-29 2016-12-08 Purdue Research Foundation Bone fracture repair by targeting of agents that promote bone healing
CN106039316B (zh) * 2016-05-03 2019-04-02 同济大学 一种基于多肽构建的成骨细胞靶向载体及其制备与应用
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060199765A1 (en) * 1998-12-31 2006-09-07 Gardella Thomas J PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
JP2010523671A (ja) * 2007-04-09 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー コラーゲン結合領域と副甲状腺ホルモンとの融合タンパク
JP2010526543A (ja) * 2007-05-11 2010-08-05 エノビア ファルマ インコーポレイテッド 骨標的アルカリホスファターゼ、キット及びその使用方法
US20150246957A1 (en) * 2012-08-28 2015-09-03 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARRIGHI I ET AL: "Bone healing induced by local delivery of an engineered parathyroid hormone prodrug", BIOMATERIALS, ELSEVIER, AMSTERDAM, NL, vol. 30, no. 9, (2009), pages 1763 - 1771, DOI: 10.1016/J.BIOMATERIALS.2008.12.023 *

Also Published As

Publication number Publication date
US20210283227A1 (en) 2021-09-16
CA3045458A1 (en) 2018-06-07
RU2019119701A (ru) 2021-01-14
AU2017367699A1 (en) 2019-07-11
JP2020500871A (ja) 2020-01-16
RU2019119701A3 (enExample) 2021-02-16
BR112019011070A2 (pt) 2019-10-01
US20200316174A1 (en) 2020-10-08
EP3548012A4 (en) 2020-07-22
WO2018102616A1 (en) 2018-06-07
EP3548012A1 (en) 2019-10-09
JP2023029957A (ja) 2023-03-07
MX2019006189A (es) 2019-11-18
IL266977B1 (en) 2023-09-01
IL266977A (en) 2019-07-31
IL266977B2 (en) 2024-01-01
US10960054B2 (en) 2021-03-30
JP7649624B2 (ja) 2025-03-21
US20200317745A1 (en) 2020-10-08
CN110114065A (zh) 2019-08-09
AU2017367699A8 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
US10960054B2 (en) Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
JP5270799B2 (ja) 副甲状腺ホルモンを低減する治療剤
JP4541899B2 (ja) ラクタム架橋を有する、コンホメーションが制限された副甲状腺ホルモン（ｐｔｈ）アナログ
JP4334480B2 (ja) α−ヘリックス安定化剤を用いる高次構造的に制約された副甲状腺ホルモン
JP2000516579A (ja) 腸栄養性ｇｌｐ―２ペプチドのアンタゴニスト
AU2002339843B2 (en) Conformationally constrained parathyroid hormone (PTH) analogs
JP2024506435A (ja) 化合物、組成物、および骨折を処置するための使用方法
JP4871128B2 (ja) 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ
CN112672747B (zh) 用于激活骨祖细胞中细胞信号传导的肽
US20230390363A1 (en) Compounds, Compositions and Methods of Use to Treat Spinal Fusions
JP5529014B2 (ja) 部位特異的なペグ化をされた直鎖状のサケカルシトニン類似体
TW201734035A (zh) 胜肽類似物
RU2785401C2 (ru) Направленная регенерация переломанной кости посредством стимуляции рецептора паратиреоидного гормона
CN116801900A (zh) 用于治疗骨折的化合物、组合物和使用方法
HK40050388A (en) Peptides for activation of cell signaling in osteoprogenitor cells
TW200817439A (en) PTH receptor modulators and uses thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 33 , NO 26 , PAGE(S) 3799 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME PURDUE RESEARCH FOUNDATION, APPLICATION NO. 2017367699, UNDER INID (72) CORRECT THE CO-INVENTOR TO NIELSEN, JEFFREY JAY HOWARD

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ LOW, PHILIP S.; LOW, STEWART ANDREW AND NIELSEN, JEFFERY JAY HOWARD